Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer

Fig. 1

A Schematic therapy regime of single dose (pink) and fractionated dose (violet) of [177Lu]Lu-PSMA-I&T. Tumor growth was monitored weekly via [18F]FDG-PET/CT (blue arrows). Day 0 marks the start of the treatment. B Tumor growth curve in control (gray), single dose (pink) and fractionated dose therapy (violet) animals (n ≥ 5); ** p = 0.002, *** p < 0.001). C Waterfall plot analysis of tumor volumes on the day of finalization. Volumetric differences were significant for the single dose (** p = 0.003) and fractionated dose (** p = 0.001) treated animals when compared to the control group

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us